OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice

Journal of Clinical Investigation

Volumn 117, Issue 11, 2007, Pages 3330-3338

  Zaini, Jamal ^a   Andarini, Sita ^a   Tahara, Minoru ^a   Saijo, Yasuo ^a   Ishii, Naoto ^b   Kawakami, Kazuyoshi ^a   Taniguchi, Masaru ^c   Sugamura, Kazuo ^b   Nukiwa, Toshihiro ^a   Kikuchi, Toshiaki ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c RIKEN Center for Integrative Medical Sciences   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD134 ANTIGEN; CD69 ANTIGEN; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; LYMPHOCYTE ACTIVATION; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; IMMUNITY, CELLULAR; INTERFERON TYPE II; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; RECEPTORS, OX40; TUMOR NECROSIS FACTOR-ALPHA; TUMOR NECROSIS FACTORS;

EID: 36048956341     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI32693     Document Type: Article

References (64)

1. Banchereau, J., et al. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767-811.
2. Steinman, R.M. 2003. Some interfaces of dendritic cell biology. APMIS. 111:675-697.
3. Sugamura, K., Ishii, N., and Weinberg, A.D. 2004. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat. Rev. Immunol. 4:420-431.
4. Salek-Ardakani, S., and Croft, M. 2006. Regulation of CD4 T cell memory by OX40 (CD134). Vaccine. 24:872-883.
5. Croft, M. 2003. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat. Rev. Immunol. 3:609-620.
6. Lanzavecchia, A., and Sallusto, F. 2001. Regulation of T cell immunity by dendritic cells. Cell. 106:263-266.
7. Munz, C., Steinman, R.M., and Fujii, S. 2005. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J. Exp. Med. 202:203-207.
8. Liu, Y.J. 2001. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell. 106:259-262.
9. Seino, K., Motohashi, S., Fujisawa, T., Nakayama, T., and Taniguchi, M. 2006. Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci. 97:807-812.
10. Mercer, J.C., Ragin, M.J., and August, A. 2005. Natural killer T cells: rapid responders controlling immunity and disease. Int. J. Biochem. Cell Biol. 37:1337-1343.
11. Kronenberg, M. 2005. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23:877-900.
12. Godfrey, D.I., and Kronenberg, M. 2004. Going both ways: immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. 114:1379-1388. doi:10.1172/JCI200423594.
13. Van Kaer, L., and Joyce, S. 2005. Innate immunity: NKT cells in the spotlight. Curr. Biol. 15:R429-R431.
14. Berkers, C.R., and Ovaa, H. 2005. Immunotherapeutic potential for ceramide-based activators of iNKT cells. Trends Pharmacol. Sci. 26:252-257.
15. Parekh, V.V., Wilson, M.T., and Van Kaer, L. 2005. iNKT-cell responses to glycolipids. Crit. Rev. Immunol. 25:183-213.
16. Banchereau, J., and Palucka, A.K. 2005. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5:296-306.
17. Cerundolo, V., Hermans, I.F., and Salio, M. 2004. Dendritic cells: a journey from laboratory to clinic. Nat. Immunol. 5:7-10.
18. Figdor, C.G., de Vries, I.J., Lesterhuis, W.J., and Melief, C.J. 2004. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10:475-480.
19. Kikuchi, T. 2006. Genetically modified dendritic cells for therapeutic immunity. Tohoku J. Exp. Med. 208:1-8.
20. Murata, K., et al. 2000. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J. Exp. Med. 191:365-374.
21. Kopf, M., et al. 1999. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL responses after virus infection. Immunity. 11:699-708.
22. - accessory cells costimulate primed CD4 T cells through OX40 and CD30 at sites where T cells collaborate with B cells. Immunity. 18:643-654.
23. Linton, P.J., et al. 2003. Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo. J. Exp. Med. 197:875-883.
24. Flynn, S., Toellner, K.M., Raykundalia, C., Goodall, M., and Lane, P. 1998. CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J. Exp. Med. 188:297-304.
25. Rogers, P.R., Song, J., Gramaglia, I., Killeen, N., and Croft, M. 2001. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity. 15:445-455.
26. Chen, A.I., et al. 1999. Ox40-ligand has a critical costimulatory role in dendritic cell: T cell interactions. Immunity. 11:689-698.
27. Bansal-Pakala, P., Jember, A.G., and Croft, M. 2001. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat. Med. 7:907-912.
28. + T cells with homology to tumor necrosis factor. J. Exp. Med. 180:757-762.
29. Gramaglia, I., et al. 2000. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J. Immunol. 165:3043-3050.
30. Gramaglia, I., Weinberg, A.D., Lemon, M., and Croft, M. 1998. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 161:6510-6517.
31. Mallett, S., Fossum, S., and Barclay, A.N. 1990. Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes-a molecule related to nerve growth factor receptor. EMBO J. 9:1063-1068.
32. Matsuda, J.L., et al. 2000. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192:741-754.
33. Benlagha, K., Weiss, A., Beavis, A., Teyton, L., and Bendelac, A. 2000. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J. Exp. Med. 191:1895-1903.
34. Marschner, A., et al. 2005. CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells. Eur. J. Immunol. 35:2347-2357.
35. Fujii, S., Liu, K., Smith, C., Bonito, A.J., and Steinman, R.M. 2004. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J. Exp. Med. 199:1607-1618.
36. Leslie, D.S., et al. 2002. CD1-mediated gamma/delta T cell maturation of dendritic cells. J. Exp. Med. 196:1575-1584.
37. Conti, L., et al. 2005. Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines. J. Immunol. 174:252-260.
38. Gerosa, F., et al. 2002. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 195:327-333.
39. Fernandez, N.C., et al. 1999. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 5:405-411.
40. Fujii, S., Shimizu, K., Kronenberg, M., and Steinman, R.M. 2002. Prolonged IFN-gamma-producing NKT response induced with alpha- galactosylceramide-loaded DCs. Nat. Immunol. 3:867-874.
41. Ferlazzo, G., and Munz, C. 2004. NK cell compartments and their activation by dendritic cells. J. Immunol. 172:1333-1339.
42. Chang, D.H., et al. 2005. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201:1503-1517.
43. Zhou, D., et al. 2004. Lysosomal glycosphingolipid recognition by NKT cells. Science. 306:1786-1789.
44. Kawano, T., et al. 1997. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science. 278:1626-1629.
45. Kinjo, Y., et al. 2005. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature. 434:520-525.
46. Mattner, J., et al. 2005. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature. 434:525-529.
47. Fujii, S., Shimizu, K., Smith, C., Bonifaz, L., and Steinman, R.M. 2003. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198:267-279.
48. Liu, K., et al. 2005. Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J. Exp. Med. 202:1507-1516.
49. Tomura, M., et al. 1999. A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J. Immunol. 163:93-101.
50. Kitamura, H., et al. 1999. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 189:1121-1128.
51. Brigl, M., Bry, L., Kent, S.C., Gumperz, J.E., and Brenner, M.B. 2003. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat. Immunol. 4:1230-1237.
52. Rahemtulla, A., et al. 1991. Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature. 353:180-184.
53. Fung-Leung, W.P., et al. 1991. CD8 is needed for development of cytotoxic T cells but not helper T cells. Cell. 65:443-449.
54. Mendiratta, S.K., et al. 1997. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity. 6:469-477.
55. Pippig, S.D., et al. 1999. Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40). J. Immunol. 163:6520-6529.
56. Cui, J., et al. 1999. Inhibition of T helper cell type 2 cell differentiation and immunoglobulin E response by ligand-activated Valpha14 natural killer T cells. J. Exp. Med. 190:783-792.
57. Nukiwa, M., et al. 2006. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors. Eur. J. Immunol. 36:1019-1027.
58. Kikuchi, T., et al. 2005. Involvement of fractalkine/CX3CL1 expression by dendritic cells in the enhancement of host immunity against Legionella pneumophila. Infect. Immun. 73:5350-5357.
59. Kikuchi, T., et al. 2004. Dendritic cells pulsed with live and dead Legionella pneumophila elicit distinct immune responses. J. Immunol. 172:1727-1734.
60. Andarini, S., et al. 2004. Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res. 64:3281-3287.
61. Kikuchi, T., et al. 2002. Tumor suppression induced by intratumor administration of adenovirus vector expressing NK4, a 4-kringle antagonist of hepatocyte growth factor, and naive dendritic cells. Blood. 100:3950-3959.
62. + T cells. Nat. Med. 6:1154-1159.
63. Kikuchi, T., and Crystal, R.G. 2001. Antigen-pulsed dendritic cells expressing macrophage-derived chemokine elicit Th2 responses and promote specific humoral immunity. J. Clin. Invest. 108:917-927. doi:10.1172/200111564.
64. Kikuchi, T., Moore, M.A.S., and Crystal, R.G. 2000. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood. 96:91-99.